Par Pharma suit + IMS ruling = off-label showdown?

Par Pharmaceuticals' ($PRX) free speech lawsuit against the FDA--coupled with recent Supreme Court action--could prompt a court battle over off-label marketing. "Par's going to blow it wide open," the Coalition for Healthcare Communication's John Kamp tells Medical Marketing & Media. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.